Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Swiss BioQuant is a bioanalytical contract research organization (CRO) based in Switzerland, providing bioanalytical services for nonclinical and clinical studies in the pharmaceutical and biotechnology industries. Based on the website content, it is not a typical SaaS or enterprise software product, but rather a specialized outsourcing service provider focused on laboratory analysis, method development, sample testing, and compliant data management.
Its core capabilities are centered on LC-MS/MS, HPLC-MS/MS, and ligand-binding assays/ELISA, covering quantitative analysis of both small and large molecules, including drugs, metabolites, biomarkers, proteins, peptides, antibodies, and oligonucleotides. The website also states that its services can support PK/PD studies and the drug development process from early discovery through clinical trials. It also extends into cell and gene therapy, using qPCR for nucleic acid quantification, vector copy number monitoring, and gene expression assessment. In addition, Swiss BioQuant provides automated data evaluation and reporting systems, as well as a validated electronic archiving system.
The website does not disclose plans, pricing, free trials, or a standardized subscription model. Given its CRO nature, services are most likely quoted on a custom basis according to project requirements, study type, sample volume, and method complexity, but this is not explicitly stated in the main content and therefore cannot be treated as confirmed information.
Its strengths lie in its deep specialization, with more than 20 years of LC-MS/MS and ELISA bioanalysis experience. It also emphasizes a 21 CFR Part 11-compliant environment, GLP compliance, and regular Swissmedic inspections, which are highly important for pharmaceutical and biotech companies. Its service coverage spans small molecules, large molecules, and cell and gene therapy, making it suitable for complex R&D projects. The downside is the lack of SaaS-related information: there is no visible mention of common enterprise software capabilities such as a customer portal, permission-based collaboration, APIs, third-party integrations, cloud deployment, or self-hosting options, and pricing is not publicly available.
It is suitable for pharmaceutical companies, biotechnology firms, and preclinical/clinical research teams that need to outsource bioanalytical work, especially R&D projects with clear requirements for GLP, 21 CFR Part 11, data archiving, and regulatory audits.
The crawled text does not provide information related to access from mainland China, service delivery, or local compliance. Access status is therefore unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on swissbioquant.com official site.
swissbioquant.com is an Switzerland Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach swissbioquant.com directly.